UOC
HLVX

UBS O'Connor’s HilleVax HLVX Stock Holding History

UBS O'Connor’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,779
Closed -$107K – 391
2024
Q4 		$107K Hold
51,779
– – ﹤0.01% 346
2024
Q3 		$91.1K Buy
51,779
+4,809
+10% +$12.3K ﹤0.01% 412
2024
Q2 		$679K Buy
46,970
+1,294
+3% +$17.8K 0.02% 346
2024
Q1 		$760K Sell
45,676
-15,383
-25% -$246K 0.02% 302
2023
Q4 		$980K Sell
61,059
-53,419
-47% -$710K 0.03% 273
2023
Q3 		$1.54M Buy
114,478
+34,000
+42% +$479K 0.03% 278
2023
Q2 		$1.38M Sell
80,478
-789
-1% -$12.2K 0.03% 347
2023
Q1 		$1.34M Buy
+81,267
New +$1.3M 0.03% 380
2022
Q4 		– Sell
-60,943
Closed -$1.04M – 148
2022
Q3 		$1.04M Sell
60,943
-30,000
-33% -$436K 0.01% 743
2022
Q2 		$994K Buy
+90,943
New +$1.08M 0.01% 766

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS O'Connor's HLVX Position: Q1 2025 in Review

UBS O'Connor sold out of HilleVax (HLVX) in Q1 2025, closing a stake of 51,779 shares — an estimated $107K sold.

UBS O'Connor first reported a position in HLVX in Q2 2022 and held it in 10 quarters. The position peaked at $1.54M in Q3 2023. 81 funds tracked by Wall St. Rank hold HLVX as of Q1 2025.

  • UBS O'Connor reported no remaining HilleVax position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 51,779 HilleVax shares in Q1 2025, an estimated $107K.
  • UBS O'Connor first reported a position in HilleVax in Q2 2022 and held it in 10 quarters.
  • UBS O'Connor's HilleVax position peaked at $1.54M in Q3 2023.
  • 81 funds tracked by Wall St. Rank held HilleVax as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.